title: The VesiVax system: a method for rapid vaccine development.
abstract: The VesiVax system is based upon the concept that highly potent vaccines can be designed by engineering proteins that are capable of stably inserting themselves into liposomes. Such a nanoscale liposomal particle can then serve as an immunogen for vaccine development. The VesiVax vaccine technology platform is designed to make it relatively easy to engineer and produce new vaccines quickly. Vaccines based on the VesiVax system have been designed against the influenza virus and herpes simplex type 2 virus, the causative agents of the "flu" and genital herpes, respectively. Both vaccines have been tested in animal models and have demonstrated significant protective efficacy from challenge with lethal doses of virus. Assays of the immunological parameters suggest that both T and B cell responses can be elicited by VesiVax vaccines. The safety profile of the VesiVax vaccines is expected to be much better than that of vaccines prepared by conventional techniques. Taken together, the inherent flexibility of the VesiVax platform is expected to facilitate the rapid development of new vaccines which are effective at stimulating protective immune responses.
authors.affiliation: Molecular Express, Inc., 2011 University Drive, Rancho Dominguez, CA 90220, USA. gfujii@molecularexpress.com
authors.forename: Gary
authors.initials: G
authors.lastname: Fujii
authors.forename: William
authors.initials: W
authors.lastname: Ernst
authors.forename: Jill
authors.initials: J
authors.lastname: Adler-Moore
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000821:virology*; D019496:Cancer Vaccines / Q000737:chemistry*; D000939:Epitopes / Q000737:chemistry; D006558:Herpes Genitalis / Q000517:prevention & control / Q000821:virology; D022301:Herpes Simplex Virus Vaccines / Q000737:chemistry; D006801:Humans; D007107:Immune System / Q000821:virology*; D007251:Influenza, Human / Q000517:prevention & control / Q000821:virology; D008081:Liposomes / Q000737:chemistry / Q000378:metabolism; D009975:Orthomyxoviridae / Q000235:genetics; D018139:Simplexvirus / Q000235:genetics; D013601:T-Lymphocytes / Q000821:virology*
chemical_list: D019496:Cancer Vaccines; D000939:Epitopes; D022301:Herpes Simplex Virus Vaccines; D008081:Liposomes